These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 36529446)

  • 1. ESMO-EURACAN Clinical Practice Guideline update for nasopharyngeal carcinoma: adjuvant therapy and first-line treatment of recurrent/metastatic disease.
    Bossi P; Chan AT; Even C; Machiels JP;
    Ann Oncol; 2023 Mar; 34(3):247-250. PubMed ID: 36529446
    [No Abstract]   [Full Text] [Related]  

  • 2. Maintenance Capecitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma-Magic Bullet or Pandora's Box?
    Ng WT; Chua MLK; Lee AWM
    JAMA Oncol; 2022 Apr; 8(4):524-525. PubMed ID: 35175303
    [No Abstract]   [Full Text] [Related]  

  • 3. Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial.
    Chen YP; Liu X; Zhou Q; Yang KY; Jin F; Zhu XD; Shi M; Hu GQ; Hu WH; Sun Y; Wu HF; Wu H; Lin Q; Wang H; Tian Y; Zhang N; Wang XC; Shen LF; Liu ZZ; Huang J; Luo XL; Li L; Zang J; Mei Q; Zheng BM; Yue D; Xu J; Wu SG; Shi YX; Mao YP; Chen L; Li WF; Zhou GQ; Sun R; Guo R; Zhang Y; Xu C; Lv JW; Guo Y; Feng HX; Tang LL; Xie FY; Sun Y; Ma J
    Lancet; 2021 Jul; 398(10297):303-313. PubMed ID: 34111416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Capecitabine Maintenance in Metastatic Nasopharyngeal Carcinoma.
    Ganguly S; Gogia A
    JAMA Oncol; 2022 Aug; 8(8):1223-1224. PubMed ID: 35771541
    [No Abstract]   [Full Text] [Related]  

  • 5. Capecitabine Maintenance in Metastatic Nasopharyngeal Carcinoma.
    S G N; Sharma A; Pramanik R
    JAMA Oncol; 2022 Aug; 8(8):1224. PubMed ID: 35771563
    [No Abstract]   [Full Text] [Related]  

  • 6. Capecitabine Maintenance in Metastatic Nasopharyngeal Carcinoma-Reply.
    Liu GY; Li WZ; Xiang YQ
    JAMA Oncol; 2022 Aug; 8(8):1224-1225. PubMed ID: 35771532
    [No Abstract]   [Full Text] [Related]  

  • 7. [Special tumor entities in the head and neck region : Nasopharyngeal carcinoma, salivary gland, and thyroid cancer].
    Zech HB; Betz CS
    HNO; 2022 Apr; 70(4):278-286. PubMed ID: 35258645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nasopharyngeal carcinoma: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
    Bossi P; Chan AT; Licitra L; Trama A; Orlandi E; Hui EP; Halámková J; Mattheis S; Baujat B; Hardillo J; Smeele L; van Herpen C; Castro A; Machiels JP; ;
    Ann Oncol; 2021 Apr; 32(4):452-465. PubMed ID: 33358989
    [No Abstract]   [Full Text] [Related]  

  • 9. Cost-effectiveness analysis of capecitabine maintenance therapy plus best supportive care vs. best supportive care alone as first-line treatment of newly diagnosed metastatic nasopharyngeal carcinoma.
    Han J; Lan X; Tian K; Shen X; He J; Chen N
    Front Public Health; 2022; 10():1086393. PubMed ID: 36777769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of capecitabine as maintenance therapy in de novo metastatic nasopharyngeal carcinoma: A propensity score matching study.
    Sun XS; Liu SL; Liang YJ; Chen QY; Li XY; Tang LQ; Mai HQ
    Cancer Commun (Lond); 2020 Jan; 40(1):32-42. PubMed ID: 32112522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis.
    Blanchard P; Lee A; Marguet S; Leclercq J; Ng WT; Ma J; Chan AT; Huang PY; Benhamou E; Zhu G; Chua DT; Chen Y; Mai HQ; Kwong DL; Cheah SL; Moon J; Tung Y; Chi KH; Fountzilas G; Zhang L; Hui EP; Lu TX; Bourhis J; Pignon JP;
    Lancet Oncol; 2015 Jun; 16(6):645-55. PubMed ID: 25957714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fractionation in patients with locoregionally advanced nasopharyngeal carcinoma.
    Lee AW; Ngan RK; Tung SY; Cheng A; Kwong DL; Lu TX; Chan AT; Chan LL; Yiu H; Ng WT; Wong F; Yuen KT; Yau S; Cheung FY; Chan OS; Choi H; Chappell R
    Cancer; 2015 Apr; 121(8):1328-38. PubMed ID: 25529384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maintenance capecitabine is beneficial in NPC.
    Killock D
    Nat Rev Clin Oncol; 2022 Apr; 19(4):220. PubMed ID: 35256771
    [No Abstract]   [Full Text] [Related]  

  • 14. Radiation recall after capecitabine in a patient with recurrent nasopharyngeal carcinoma: a case report.
    Lee V; Lam KO; Kwong D; Leung TW
    J Med Case Rep; 2016 Sep; 10(1):247. PubMed ID: 27604462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term survival in a patient with recurrent nasopharyngeal carcinoma treated with capecitabine.
    Ayyoub S; Sultan I
    Pediatr Blood Cancer; 2022 Jul; 69(7):e29605. PubMed ID: 35187809
    [No Abstract]   [Full Text] [Related]  

  • 16. Radiotherapy-induced anti-tumor immune response and immune-related adverse events in a case of recurrent nasopharyngeal carcinoma undergoing anti-PD-1 immunotherapy.
    Finazzi T; Rordorf T; Ikenberg K; Huber GF; Guckenberger M; Garcia Schueler HI
    BMC Cancer; 2018 Apr; 18(1):395. PubMed ID: 29625593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial.
    Zhang L; Huang Y; Hong S; Yang Y; Yu G; Jia J; Peng P; Wu X; Lin Q; Xi X; Peng J; Xu M; Chen D; Lu X; Wang R; Cao X; Chen X; Lin Z; Xiong J; Lin Q; Xie C; Li Z; Pan J; Li J; Wu S; Lian Y; Yang Q; Zhao C
    Lancet; 2016 Oct; 388(10054):1883-1892. PubMed ID: 27567279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiotherapy for nasopharyngeal carcinoma and combined capecitabine and nimotuzumab treatment for lung metastases in a liver transplantation recipient: a case experience of sustained complete response.
    Yan S; Jiang X; Yang J; Yan D; Wang YX
    Cancer Biother Radiopharm; 2012 Oct; 27(8):519-23. PubMed ID: 22834655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in systemic treatment for nasopharyngeal carcinoma.
    Tan WL; Tan EH; Lim DW; Ng QS; Tan DS; Jain A; Ang MK
    Chin Clin Oncol; 2016 Apr; 5(2):21. PubMed ID: 27121881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials.
    Fang W; Yang Y; Ma Y; Hong S; Lin L; He X; Xiong J; Li P; Zhao H; Huang Y; Zhang Y; Chen L; Zhou N; Zhao Y; Hou X; Yang Q; Zhang L
    Lancet Oncol; 2018 Oct; 19(10):1338-1350. PubMed ID: 30213452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.